Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Calypso: Fistula fix

Merck Serono spinout Calypso developing mAbs to treat Crohn's, celiac

Calypso Biotech S.A. has mAbs against an undisclosed target to treat fistulizing Crohn's disease, a severe form of the condition that usually is refractory to marketed therapies such as immunomodulators. The company expects it will be able to treat the disease's underlying inflammation as well as its fibrotic complications.

Co-founders and co-VPs of R&D Alain Vicari and Yolande Chvatchko worked on the human mAbs, dubbed the CALY-001 program, when they were at

Read the full 710 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE